|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
oncology
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2021
gptkb:FDA
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:atccode
|
L01 XC18
|
|
gptkbp:casnumber
|
1432020-66-0
|
|
gptkbp:chemical_formula
|
C646 H1008 N174 O198 S4
|
|
gptkbp:clinical_trial
|
positive
Phase 2
Phase 3
effective
well-tolerated
NCT03422023
NCT03422036
NCT03422010
NCT03422047
NCT03422059
|
|
gptkbp:developed_by
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:effective_date
|
March 2021
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Libtayo
|
|
gptkbp:indication
|
gptkb:cutaneous_squamous_cell_carcinoma
|
|
gptkbp:marketed_as
|
gptkb:Libtayo
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
immune checkpoint inhibitor
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:research_areas
|
gptkb:biotechnology
cancer therapy
drug development
oncology
pharmacology
clinical research
dermatology
biopharmaceuticals
therapeutics
immunology
|
|
gptkbp:route_of_administration
|
IV
intravenous infusion
|
|
gptkbp:side_effect
|
fatigue
nausea
hepatitis
diarrhea
rash
hypothyroidism
infusion-related reactions
pneumonitis
pruritus
|
|
gptkbp:structure
|
gptkb:Ig_G4_monoclonal_antibody
|
|
gptkbp:targets
|
gptkb:PD-1
|
|
gptkbp:treatment
|
gptkb:immunotherapy
|
|
gptkbp:used_for
|
gptkb:Oncology
treatment of non-small cell lung cancer
treatment of cutaneous squamous cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
4
|